Cardiac Resynchronization Therapy (CRT) Market Insights, Competitive Landscape and Market Forecast 2024-2030 [Yahoo! Finance]
Elutia, Inc. - Class A (ELUT)
Company Research
Source: Yahoo! Finance
The cardiac resynchronization therapy market was valued at USD 7.00 billion in 2023, growing at a CAGR of 6.49% during the forecast period from 2024 to 2030 to reach USD 10.18 billion by 2030. The cardiac resynchronization therapy market is observing substantial market growth primarily owing to the increasing cases of cardiovascular disorders including atrial fibrillation and coronary artery disease (CAD), innovative product developmental activities by the regulatory bodies, and the rising geriatric population that are expected to escalate the overall growth of the cardiac resynchronization therapy market during the forecast period from 2024 to 2030. Cardiac Resynchronization Therapy Market Segment Analysis: In the product type segment of cardiac resynchronization therapy, the CRT-defibrillators category is expected to have a significant revenue share in the year 2023. This is because of the widespread uses and various key features of CRT-defibrillators that enhance their utili
Show less
Read more
Impact Snapshot
Event Time:
ELUT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELUT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELUT alerts
High impacting Elutia, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
ELUT
News
- Elutia Awarded Cardiac Rhythm Management Devices Agreement with Premier, Inc.GlobeNewswire
- Elutia Inc. (NASDAQ: ELUT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $10.00 price target on the stock.MarketBeat
- Elutia Inc (ELUT) Q3 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges [Yahoo! Finance]Yahoo! Finance
- Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025 [Yahoo! Finance]Yahoo! Finance
- Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025GlobeNewswire
ELUT
Sec Filings
- 12/11/24 - Form 4
- 12/11/24 - Form 4
- 12/11/24 - Form 4
- ELUT's page on the SEC website